+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Juvenile Macular Degeneration Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768257
  • Report
  • April 2019
  • Region: Global
  • 39 pages
  • VPA Research

FEATURED COMPANIES

  • Astellas Pharma Inc
  • CHA Bio & Diostech Co Ltd
  • Lin Bioscience Inc
  • MD Stem Cells
  • Ophthotech Corp
  • Sanofi
  • MORE
The global clinical trial report- “2019 Juvenile Macular Degeneration Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Juvenile Macular Degeneration. It presents in-depth analysis of Juvenile Macular Degeneration clinical trials across markets and companies. The research work is for providing complete understanding into trends in Juvenile Macular Degeneration.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Juvenile Macular Degeneration clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Juvenile Macular Degeneration

The research work is prepared through extensive and continuous research on Juvenile Macular Degeneration trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Juvenile Macular Degeneration patients are identified
  • The report includes panorama of Juvenile Macular Degeneration clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Juvenile Macular Degeneration clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc
  • CHA Bio & Diostech Co Ltd
  • Lin Bioscience Inc
  • MD Stem Cells
  • Ophthotech Corp
  • Sanofi
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Juvenile Macular Degeneration Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Juvenile Macular Degeneration Clinical Trials by Region
2.2.2 Average Enrollment of Juvenile Macular Degeneration Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Juvenile Macular Degeneration Treatment, 2019

3. Region wise Juvenile Macular Degeneration Clinical Trials
3.1 Asia Pacific Juvenile Macular Degeneration Clinical Trials by Country
3.2 Europe Juvenile Macular Degeneration Clinical Trials by Country
3.3 North America Juvenile Macular Degeneration Clinical Trials by Country
3.4 Middle East and Africa Juvenile Macular Degeneration Clinical Trials by Country
3.5 South and Central America Juvenile Macular Degeneration Clinical Trials by Country

4. Juvenile Macular Degeneration Clinical Trial Trends
4.1 Start Year wise Juvenile Macular Degeneration Clinical Trials
4.2 Phase wise Juvenile Macular Degeneration Clinical Trials
4.3 Trial Status wise Juvenile Macular Degeneration Clinical Trials
4.4 Trial Type wise Juvenile Macular Degeneration Clinical Trials

5. Juvenile Macular Degeneration Average Enrollment Trends
5.1 Average Enrollment in Juvenile Macular Degeneration Trials by Year
5.2 Average Enrollment in Juvenile Macular Degeneration Trials by Phase
5.3 Average Enrollment in Juvenile Macular Degeneration Trials by Status
5.4 Average Enrollment in Juvenile Macular Degeneration Trials by Type of Trial

6. Companies Participating in Juvenile Macular Degeneration Clinical Trials
6.1 Juvenile Macular Degeneration Trials by Sponsor Type
6.2 Juvenile Macular Degeneration Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Juvenile Macular Degeneration Trials- Phase 1
7.2 Juvenile Macular Degeneration Trials- Phase 2
7.3 Juvenile Macular Degeneration Trials- Phase 3
7.4 Juvenile Macular Degeneration Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Juvenile Macular Degeneration Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Figure 5: Europe - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Figure 7: North America - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Figure 9: Juvenile Macular Degeneration Clinical Trials by Phase
Figure 10: Juvenile Macular Degeneration Clinical Trials by Trial Status
Figure 11: Juvenile Macular Degeneration Clinical Trials by Type
Figure 12: Juvenile Macular Degeneration Clinical Trials by Sponsor Type
Figure 13: Juvenile Macular Degeneration Clinical Trials by Leading Sponsors
Figure 14: Juvenile Macular Degeneration Average Enrollment by Phase
Figure 15: Juvenile Macular Degeneration Average Enrollment by Trial Status
Figure 16: Juvenile Macular Degeneration Average Enrollment by Type
Figure 17: Juvenile Macular Degeneration- Average Enrolment by Type of Sponsors
Figure 18: Juvenile Macular Degeneration- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Juvenile Macular Degeneration Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Table 5: Europe - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Table 7: North America - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Juvenile Macular Degeneration Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Juvenile Macular Degeneration Average Enrollment by Phase
Table 15: Juvenile Macular Degeneration Average Enrollment by Trial Status
Table 16: Juvenile Macular Degeneration Average Enrollment by Type
Table 17: Juvenile Macular Degeneration- Average Enrolment by Type of Sponsors
Table 18: Juvenile Macular Degeneration- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • CHA Bio & Diostech Co Ltd
  • Kubota Pharmaceutical Holding
  • Lin Bioscience Inc
  • MD Stem Cells
  • Ophthotech Corp
  • Sanofi
  • Vision Medicines Inc
  • Visum Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll